FDA's Peter Marks overrode reviewers' call to reject Sarepta's new Duchenne gene therapy - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
Peter Marks, the senior FDA official who oversees the regulation of gene therapies, overrode agency reviewers’ decision to reject Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy after he disagreed with parts of their interpretation of the limit…